NEWS OF MEDICINE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

- -

References

  1. Chen R., Zinzani P.L., Lee H.J., et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1 144-1 153. doi: 10.1182/blood.2019000324.
  2. Allen P.B., Chen Q.C., Lu X., et al. Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma: updated results and correlative analysis [ASH abstract 231]. Blood. 2021;138(suppl 1).
  3. Лимфома Ходжкина. Клинические рекомендации. Одобрено на заседании Научно-практического совета Министерства здравоохранения Российской Федерации (протокол от «10» апреля 2020 г. № 17/2-3-4).

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies